polatuzumab vedotin,lenalidomide
gilead,roche,novartis
['great work', ' lena', 'descar-t', 'lenalidomide', 'lymsm', 'lymphoma', ' pola ', 'dlbcl']
regarding our data on checkpoint inhibitors: now 3 datasets presented #ash22 that survival is abysmal with pd1/pdl1 blockade in relapsed disease after car-t. great work by drs. &amp; erbella that bispecifics &amp; pola have much better salvage outcomes. #lymsm #tcellrx 
#lymsm & #mmsm hematologist & patient-reported outcomes researcher @CUHematology. Founder of https://t.co/kN6qeGXfg5, @inTrainingDoc & @inHouseMag. ??????